lutetium (177lu) oxodotreotide
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT04711135)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Also known as
- lutetium (177lu) oxodotreotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05884255 | Phase 3 | Jul 6, 2023 | Hengrui Therapeutics, Inc. |
| NCT04711135 | Phase 2 | Dec 31, 2021 | Advanced Accelerator Applications, Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanced Accelerator Applications | For profit | 1 | 1 | 1 | 2021 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Novartis | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1